Valeant Pharmaceuticals International, Inc.
) recently closed the acquisition of Russia-based Natur Produkt
International, JSC for $163 million in addition to adjustments
for net debt and working capital.
The acquisition was announced in Mar 2012. The erstwhile Natur
Produkt was a major player in the over-the-counter (OTC) segment,
powered by key drugs such as AntiGrippin, a leading cough and
cold remedy, and Anti Angin, Sage and Eucaplyptus MA brand names,
leading sore throat remedies.
We remind investors that Valeant Pharma, a Canada-based
specialty pharmaceutical company, has been quite active on the
acquisition front in recent times with the largest being
The company realized incremental product sales revenue of
$76.6 million in the third quarter, from acquisitions made in
2012, primarily by Probiotica, OraPharma, Gerot Lannach, Pedinol
Pharmacal, Inc., University Medical, Swiss Herbal Remedies
Limited and Atlantis.
In Dec 2012, Valeant Pharma acquired all of the outstanding
common stock of Medicis Pharmaceutical Corporation for
approximately $2.6 billion.
The erstwhile Medicis Pharma focused on the development and
marketing of products for the treatment of dermatological and
aesthetic conditions in the US. Key products include Solodyn,
Perlane, Restylane, Ziana, Dysport and Zyclara. The acquisition
has further strengthened Valeant Pharma's product portfolio in
the dermatological field.
We note that acquisition activity has been quite strong in
recent times in the dermatological segment. Apart from Valeant
Pharma's acquisition of Medicis Pharma, the acquisition of
specialty dermatology generics company, Fougera Pharma by
) in Jul 2012, was also in the news.
) acquired privately-held SkinMedica, Inc. in Dec 2012 with a
focus on the latter's topical aesthetics skin care
Valeant Pharma remains a top pick with a Zacks Rank #1 (Strong
Salix Pharmaceuticals Ltd.
) also looks attractive with a Zacks Rank #1.
ALLERGAN INC (AGN): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
VALEANT PHARMA (VRX): Free Stock Analysis
To read this article on Zacks.com click here.